{"groups":[{"description":"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.\n\nbevacizumab: Given IV\n\nlenalidomide: Given orally\n\ndexamethasone: Given orally","id":"FG000","title":"Bevacizumab, Dexamethasone, and Lenalidomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Started Non-Protocol Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Stopped treatmen to collect stem cells"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Transferred to another Institution"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"39"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"No events between enrollment and group assignment. All subjects enrolled are immediately assigned to Arm 1, \"Bevacizumab, Dexamethasone, and Lenalidomide.\"","recruitmentDetails":"Participants were recruited from the University of Wisconsin (UW) Hospital and Clinics, the UW 1 South Park Clinic, and the Wisconsin Oncology Network (WON) clinics between November 2006 and March 2011."}